Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2546)	8/3/2009 12:53:32 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ONTY is up 27% with volume about 8x its ADV.<g> The stock continued its recent UT as it opened with a good UG bigcharts.marketwatch.com It announced that clinical data relating to long-term treatment with Stimuvax were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer in Frisco on Aug 1. The presentation involved 16 patients who received treatment with Stimuvax for between 2 and 8.2 years as part of the PIIb in patients with stage IIIb/IV NSCLC.Ten of the 16 studied patients were alive without evidence of disease progression, of whom 8 continued to receive therapy with Stimuvax after 6.3 to 8.2 years. The remaining 2 living patients discontinued Stimuvax therapy after 2.4 and 5.8 years, respectively, and were without evidence of disease progression. Nine of the 10 living patients had stage IIIb NSCLC upon entry to the trial, while one had stage IV disease. Six of the 10 living patients had a complete response to their first-line chemotherapy or chemo-radiation, while four patients had stable disease. The remaining 6 of the 16 patients discontinued Stimuvax after 2.0 to 5.1 years of treatment as a result of disease progression and are deceased. With some further good news, it seems that the stock still has plenty of room to run.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2546)	9/25/2009 2:01:15 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

KERX has already closed its last UG of Wednesday, Sep23 and is up today 8.23% with volume of > 5,207,100 which is > 2x its ADV bigcharts.marketwatch.com The last UG on Wednesday was after it announced results of the OLE trial of Zerenex for the treatment of hyperphosphatemia. That trial, conducted in Taiwan,was to examine the safety and efficacy of Zerenex as a phosphate binder.The PII lasted < 28 days, but the average patients' participation in the OLE trial was 306 +/- 85 days, and the data on the serum Phosphorous level throughout the trial was 5.22mg/dL, within the normal range as recommended by the KDOQI guidelines and there were no Zerenex-related serious adverse events. The study suggests that Zerenex can maintain patients within the normal serum phosphorous range for extended periods of time and that the drug appears to be well-tolerated.The drug may reduce the need for IV iron or EPO in the dialysis patient population. It is expected that the results can be replicated in an upcoming PIII. <g> KERX has NSLTD, and as mentioned,with some good news the stock could get to close its March 2008 DG. <g> bigcharts.marketwatch.com Bernard